Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Cash from Financing Activities: 2023-2025

Historic Cash from Financing Activities for Corvus Pharmaceuticals (CRVS) over the last 2 years, with Sep 2025 value amounting to $360,000.

  • Corvus Pharmaceuticals' Cash from Financing Activities rose 620.00% to $360,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $55.0 million, marking a year-over-year increase of 595.98%. This contributed to the annual value of $49.0 million for FY2024, which is 524.16% up from last year.
  • Latest data reveals that Corvus Pharmaceuticals reported Cash from Financing Activities of $360,000 as of Q3 2025, which was down 98.99% from $35.8 million recorded in Q2 2025.
  • Corvus Pharmaceuticals' Cash from Financing Activities' 5-year high stood at $35.8 million during Q2 2025, with a 5-year trough of $4,000 in Q1 2023.
  • For the 3-year period, Corvus Pharmaceuticals' Cash from Financing Activities averaged around $7.9 million, with its median value being $347,500 (2023).
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first slumped by 85.07% in 2024, then surged by 620.00% in 2025.
  • Corvus Pharmaceuticals' Cash from Financing Activities (Quarterly) stood at $335,000 in 2023, then tumbled by 85.07% to $18.6 million in 2024, then surged by 620.00% to $360,000 in 2025.
  • Its Cash from Financing Activities was $360,000 in Q3 2025, compared to $35.8 million in Q2 2025 and $279,000 in Q1 2025.